Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort

Bajpai, Jyoti; Kashyap, Lakhan; Vallathol, Dilip Harindran; Das, Ankita; Singh, Manoj; Pathak, Rima; Rath, Sushmita; Sekar, Anbarasan; Mohanta, Subham; Reddy, Asha; Joshi, Shalik Ram; Nandhana, Ravindra; Ravind, Rahul; Wadasadawala, Tabassum; Nair, Nita; Ghosh, Jaya; Parmar, Vani; Gulia, Seema; Desai, Sangeeta; Shet, Tanuja; Thakur, Meenakshi; Patil, Asawari; Sarin, Rajiv; Gupta, Sudeep; Badwe, Rajendra

doi:10.1016/j.breast.2022.03.011

Cited by 5 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data from an Indian study strongly indicate need for early detection of triple-negative BC (TNBC) in young patients and augmentation of therapy in addition to standard Taxane and Anthracycline-based chemotherapy in view of overall inferior outcomes. [47][48][49] The phase III KEYNOTE 522 study compared Pembrolizumab with chemotherapy versus placebo with chemotherapy followed by a year of pembrolizumab or placebo, respectively. The most recently updated data shown benefit of pCR (64.8% vs. 51.2%, p ¼ 0.00055) and for EFS (91.3% vs. 85.3%, hazard ratio [HR]: 0.63, 95% confidence interval [CI]: 0.43-0.93) favoring the pembrolizumab arm.…”

Section: Neo/adjuvant Chemotherapymentioning

confidence: 99%

Indian Society of Medical and Paediatric Oncology (ISMPO)—Breast Cancer in Young Guidelines

Bajpai,

Gandhi,

Rajappa

et al. 2024

Indian J Med Paediatr Oncol

Self Cite

View full text Add to dashboard Cite

Breast cancer (BC) is the most common type of cancer globally and in India. In India, BC is more common among younger women compared with Western counterparts. Younger women with BC tend to have a less favorable outcome as they are more likely to have aggressive tumors. Younger women are not well represented in BC management studies as the median age at diagnosis is in the late 50s to early 60s. This can lead to difficulty in using risk-stratification models and molecular tools among young BC patients and may result in overtreatment. Therefore, Indian Society of Medical and Pediatric Oncology gathers and organizes available evidence from published literature to create a guide specifically for young BC patients in low- and middle-income countries like India.

show abstract

Section: Neo/adjuvant Chemotherapymentioning

confidence: 99%